A statement released earlier today by N+1 Singer about Synairgen PLC (LON:SNG) bumps down the target price to 46.00GBX
- Updated: September 24, 2016
Stating as potential upside of 0.31%, N+1 Singer dropped the price target of Synairgen PLC (LON:SNG) to 46.00GBX
On 8/30/2016, finnCap released a statement on Synairgen PLC (LON:SNG) maintained the target price at 137.00GBX that suggested an upside of 0%.
Having a price of 35.00GBX, Synairgen PLC (LON:SNG) traded -2.90% lower on the day. With the last close up 11.27% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Synairgen PLC has recorded a 50-day average of 34.30GBX and a two hundred day average of 30.11GBX. Volume of trade was down over the average, with 6,004 shares of SNG changing hands under the typical 43,164
With a total market value of 0 GBX, Synairgen PLC has with a one year low of 19.00GBX and a one year high of 38.00GBX .
A total of 2 analysts have released a report on Synairgen PLC. zero analysts rating the company a strong buy, one analyst rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 87.00GBX.
More About Synairgen PLC (LON:SNG)
Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.